This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Chronic hepatitis B virus hepatitis

Authoring team

Chronic hepatitis B is defined as persistence of hepatitis B surface antigen (HBsAg) for 6 months or more after acute infection

  • 2-10% of immunocompetent adults fail to clear HBsAg from the blood and develop chronic infection.

The risk of chronic infection with hepatitis B virus depends on the nature of the immune response to the initial infection. This varies according to the age at which the infection is acquired (2)


outcome

neonates

children

adults

chronic infection

90%

30%

1-5%

recover

10%

70%

95-99%

In some people, chronic hepatitis B is inactive and does not present significant health problems, but others may progress to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)

  • progression of liver disease is associated with hepatitis B virus (HBV) DNA levels in the blood
  • without antiviral treatment, the 5-year cumulative incidence of cirrhosis ranges from 8 to 20%. People with cirrhosis face a significant risk of decompensated liver disease if they remain untreated
  • five-year survival rates among people with untreated decompensated cirrhosis can be as low as 15%

Chronic hepatitis B can be divided into e antigen- (HBeAg) positive or HBeAg negative disease based on the presence or absence of e antigen. The presence of HBeAg is typically associated with higher rates of viral replication and therefore increased infectivity

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.